These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30558053)

  • 1. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment.
    Liao X; Li H; Liu Z; Liao S; Li Q; Liang C; Huang Y; Xie M; Wei J; Li Y
    Medicine (Baltimore); 2018 Dec; 97(50):e13635. PubMed ID: 30558053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
    Leng J; Li DR; Huang LM; Ji XH; Wang DL
    Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
    Chen H; Xue L; Liu L; Li P
    J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
    Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
    Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.
    Yang H; Chen M; Mei Z; Xie C; Zhou Y; Qiu H
    Cancer Med; 2021 Jul; 10(13):4282-4290. PubMed ID: 33987959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.
    Rong X; Liu H; Yu H; Zhao J; Wang J; Wang Y
    Invest New Drugs; 2022 Apr; 40(2):340-348. PubMed ID: 34997351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer patients with poor performance status.
    Chen J; Wang J; Miao Q
    Medicine (Baltimore); 2019 Nov; 98(45):e17890. PubMed ID: 31702665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
    Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
    Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
    Yang C; Feng W; Wu D
    J Cancer Res Ther; 2018 Jan; 14(1):159-162. PubMed ID: 29516980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
    Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
    Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
    Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
    [No Abstract]   [Full Text] [Related]  

  • 13. Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study.
    Wang F; Yuan X; Jia J; Bi X; Zhou Z; Zhou Q; Li X; Luo C; Deng M; Yi L; Li Y; Lu J; Su W; Chen H; Zhu Y; Wang S
    Sci Rep; 2020 Apr; 10(1):6058. PubMed ID: 32269247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
    Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
    Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
    Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.
    Liu C; Jia Q; Wei H; Yang X; Liu T; Zhao J; Ling Y; Wang C; Yu H; Li Z; Jiao J; Wu Z; Yang C; Xiao J
    Lancet Oncol; 2020 Sep; 21(9):1244-1252. PubMed ID: 32888455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of apatinib for elderly patients with previously treated extensive-stage colorectal cancer patients and the prognostic significance of common adverse reactions.
    Yu Y; Li Y; Xu C; Zhang W
    Indian J Cancer; 2024 Apr; 61(2):317-323. PubMed ID: 36861718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
    Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
    Zhang X; Xiong Y; Xia Q; Wu F; Liu L; Zhou Y; Zeng L; Zhou C; Xia C; Jiang W; Liao D; Xiao L; Liu L; Yang H; Guan R; Li K; Wang J; Lei G; Zhang Y; Yang N
    JAMA Netw Open; 2020 Mar; 3(3):e201226. PubMed ID: 32191330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effect of apatinib combined chemotherapy as second-line or above therapy in patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.
    Zhang F; Yin Y; Ni T; Zhang M; Zhou Z; Sun X; Kuang W; Li P
    Pharmazie; 2020 Aug; 75(8):389-394. PubMed ID: 32758339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.